CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6854-6866

  Murillo Sauca, Oihana ^a,b   Chung, Man Ki ^a,b   Shin, June Ho ^a,b   Karamboulas, Christina ^c   Kwok, Shirley ^a   Jung, Young Ho ^a,b   Oakley, Richard ^a,b   Tysome, James R ^a,b   Farnebo, Lovisa O ^a,b   Kaplan, Michael J ^a,b   Sirjani, Davud ^a,b   Divi, Vasu ^a,b   Christopher Holsinger, F ^a,b   Tomeh, Chafeek ^a,b   Nichols, Anthony ^d   Le, Quynh T ^a,b   Dimitrios Colevas, A A ^a,b   Kong, Christina S ^a,b   Uppaluri, Ravindra ^e   Lewis, James S ^e   Ailles, Laurie E ^c   Sunwoo, John B ^a,b   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Cancer initiating cell; CD44; HNSCC; NGFR; P75NTR

Indexed keywords

CD271 ANTIGEN; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P16; PROTEIN P75; TUMOR ANTIGEN; UNCLASSIFIED DRUG; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGFR PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HYPOPHARYNX CANCER; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INCUBATION TIME; LARYNX CANCER; LENTIVIRINAE; METASTASIS POTENTIAL; MOUSE; MOUTH CARCINOMA; MOUTH MUCOSA; NONHUMAN; OROPHARYNX CARCINOMA; PLASMID; PREVALENCE; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL; TUMOR INITIATING CELL; WART VIRUS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER STEM CELL; CELL GROWTH; DRUG SCREENING; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HEAD AND NECK NEOPLASMS; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PHOSPHORYLATION; RECEPTORS, NERVE GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907080881     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2269     Document Type: Article

References (38)

1. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007; 104(3):973-978.
2. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458(7239):780-783.
3. Chinn SB, Darr OA, Owen JH, Bellile E, McHugh JB, Spector ME, Papagerakis SM, Chepeha DB, Bradford CR, Carey TE and Prince ME. Cancer stem cells: Mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck. 2014.
4. Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME and Ailles LE. Frequency of cells expressing CD44, a Head and Neck cancer stem cell marker: Correlation with tumor aggressiveness. Head Neck. 2011.
5. Nakamura T, Endo K-I and Kinoshita S. Identification of human oral keratinocyte stem/progenitor cells by neurotrophin receptor p75 and the role of neurotrophin/p75 signaling. Stem Cells. 2007; 25(3):628-638.
6. Thompson SJ, Schatteman GC, Gown AM and Bothwell M. A monoclonal antibody against nerve growth factor receptor. Immunohistochemical analysis of normal and neoplastic human tissue. Am J Clin Pathol. 1989; 92(4):415-423.
7. Casaccia-Bonnefil P, Gu C and Chao MV. Neurotrophins in cell survival/death decisions. Advances in experimental medicine and biology. 1999; 468:275-282.
8. Yan H, Schlessinger J and Chao MV. Chimeric NGF-EGF receptors define domains responsible for neuronal differentiation. Science. 1991; 252(5005):561-563.
9. Sailer MH, Gerber A, Tostado C, Hutter G, Cordier D, Mariani L and Ritz MF. Non-invasive neural stem cells become invasive in vitro by combined FGF2 and BMP4 signaling. Journal of cell science. 2013; 126(Pt 16):3533-3540.
10. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT and Weissman IL. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010; 466(7302):133-137.
11. Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M and Sommer L. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011; 71(8):3098-3109.
12. Huang S-D, Yuan Y, Liu X-H, Gong D-J, Bai C-G, Wang F, Luo J-H and Xu Z-Y. Self-renewal and chemotherapy resistance of p75NTR positive cells in esophageal squamous cell carcinomas. BMC Cancer. 2009; 9:9.
13. Okumura T, Shimada Y, Imamura M and Yasumoto S. Neurotrophin receptor p75(NTR) characterizes human esophageal keratinocyte stem cells in vitro. Oncogene. 2003; 22(26):4017-4026.
14. Imai T, Tamai K, Oizumi S, Oyama K, Yamaguchi K, Sato I, Satoh K, Matsuura K, Saijo S, Sugamura K and Tanaka N. CD271 defines a stem cell-like population in hypopharyngeal cancer. PLoS One. 2013; 8(4):e62002.
15. Kiyosue T, Kawano S, Matsubara R, Goto Y, Hirano M, Jinno T, Toyoshima T, Kitamura R, Oobu K and Nakamura S. Immunohistochemical location of the p75 neurotrophin receptor (p75NTR) in oral leukoplakia and oral squamous cell carcinoma. International journal of clinical oncology. 2013; 18(1):154-163.
16. Okumura T, Tsunoda S, Mori Y, Ito T, Kikuchi K, Wang TC, Yasumoto S and Shimada Y. The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma. Clin Cancer Res. 2006; 12(17):5096-5103.
17. Tsunoda S, Okumura T, Ito T, Mori Y, Soma T, Watanabe G, Kaganoi J, Itami A, Sakai Y and Shimada Y. Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma. Br J Cancer. 2006; 95(3):322-330.
18. Soland TM, Brusevold IJ, Koppang HS, Schenck K and Bryne M. Nerve growth factor receptor (p75 NTR) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma. Histopathology. 2008; 53(1):62-72.
19. Lee R, Kermani P, Teng KK and Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science. 2001; 294(5548):1945-1948.
20. Massa SM, Xie Y, Yang T, Harrington AW, Kim ML, Yoon SO, Kraemer R, Moore LA, Hempstead BL and Longo FM. Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J Neurosci. 2006; 26(20):5288-5300.
21. Moscatelli I, Pierantozzi E, Camaioni A, Siracusa G and Campagnolo L. p75 neurotrophin receptor is involved in proliferation of undifferentiated mouse embryonic stem cells. Exp Cell Res. 2009; 315(18):3220-3232.
22. Cragnolini AB and Friedman WJ. The function of p75NTR in glia. Trends Neurosci. 2008; 31(2):99-104.
23. Roux PP and Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Progress in neurobiology. 2002; 67(3):203-233.
24. Eyler CE and Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008; 26(17):2839-2845.
25. Mi Z, Rogers DA, Mirnics ZK and Schor NF. p75NTR-dependent modulation of cellular handling of reactive oxygen species. J Neurochem. 2009; 110(1):295-306.
26. Nor C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman JI, Roesler R and Nor JE. Cisplatin induces bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia. 2014; 16(2):137-IN138.
27. Fagan JJ, Collins B, Barnes L, D'Amico F, Myers EN and Johnson JT. Perineural invasion in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1998; 124(6):637-640.
28. Davies AM, Bandtlow C, Heumann R, Korsching S, Rohrer H and Thoenen H. Timing and site of nerve growth factor synthesis in developing skin in relation to innervation and expression of the receptor. Nature. 1987; 326(6111):353-358.
29. Tosaki T, Kamiya H, Yasuda Y, Naruse K, Kato K, Kozakae M, Nakamura N, Shibata T, Hamada Y, Nakashima E, Oiso Y and Nakamura J. Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons. Experimental neurology. 2008; 213(2):381-387.
30. Chan M and Tahan S. Low-affinity nerve growth factor receptor (P75 NGFR) as a marker of perineural invasion in malignant melanomas. J Cutan Pathol. 2009.
31. Kolokythas A, Cox DP, Dekker N and Schmidt BL. Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? J Oral Maxillofac Surg. 2010; 68(6):1290-1295.
32. Yu EH, Lui MT, Tu HF, Wu CH, Lo WL, Yang CC, Chang KW and Kao SY. Oral carcinoma with perineural invasion has higher nerve growth factor expression and worse prognosis. Oral diseases. 2014; 20(3):268-274.
33. Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M and Buchler MW. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol. 1999; 17(8):2419-2428.
34. Blo¨chl A and Blo¨chl R. A cell-biological model of p75NTR signaling. J Neurochem. 2007; 102(2):289-305.
35. Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL and Lewis JS, Jr. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. The American journal of surgical pathology. 2011; 35(9):1343-1350.
36. Lewis JS, Jr., Ukpo OC, Ma XJ, Flanagan JJ, Luo Y, Thorstad WL and Chernock RD. Transcriptionally-active high-risk human papillomavirus is rare in oral cavity and laryngeal/hypopharyngeal squamous cell carcinomas-a tissue microarray study utilizing E6/E7 mRNA in situ hybridization. Histopathology. 2012; 60(6):982-991.
37. Lewis JS, Jr., Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q and El-Mofty SK. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. The American journal of surgical pathology. 2010; 34(8):1088-1096.
38. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS, Jr., Dunn GP, Bui JD, Sunwoo JB and Uppaluri R. ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness. Cancer Res. 2012; 72(1):365-374.